Roche Pharmaceutical Development and Sales Overview
Tecentriq overview: Adjuvant key trials now to read out in 2023
First PD-(L)1 with pivotal SC results to be filed in 2022
Roche
CHFM
1,000
YoY CER growth
+9%
900
800
+23%
+49%
700
600
+154%
500
400
300
200
100
0
Q3 19
Q3 20
Q3 21
Q3 22
US
Europe International Japan
Tecentriq Q3 update
• Positive Ph III (IMscin001) results for SC administration
Lung franchise (NSCLC, SCLC)
•
EU: Strong launch in adj. NSCLC; 1L SCLC with continued
growth
• US: Continued strong launch in adj. NSCLC
Gl franchise (HCC)
•
US/EU/Japan: Further growth in 1L HCC
Outlook 2022
• Further growth due to first-to-market indications
CER-Constant Exchange Rates; SC-subcutaneous; NSCLC-non-small cell lung cancer; SCLC-small cell lung cancer; HCC-hepatocellular cancer
22
22View entire presentation